Need Help?

Detection of clinically relevant genetic and transcriptomic landscape in DLBCL uniformly treated by R-CHOP

Recent studies using next-generation sequencing strategies have described the landscape of genetic alterations in diffuse large B-cell lymphoma (DLBCL). However, little is known about the clinical relevance of recurrent mutations and copy number alterations and their transcriptional footprints. This study examines the frequency, interaction and clinical impact of recurrent genetic aberrations in DLBCL using high-resolution technologies in a large population-based cohort.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001003783 Illumina HiSeq 2000 Illumina HiSeq 2500 376
EGAD00010001980 Affymetrix SNP6.0 341
Publications Citations
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.
Nat Med 26: 2020 577-588
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
Cancer Cell 37: 2020 551-568.e14
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome.
J Exp Med 217: 2020 e20200483
PRPS-ST: A protocol-agnostic self-training method for gene expression-based classification of blood cancers.
Blood Cancer Discov 1: 2020 244-257
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.
Blood Adv 5: 2021 71-83
Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis.
Immunity 54: 2021 1807-1824.e14
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.
Cancer Cell 39: 2021 1422-1437.e10
Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.
Mol Oncol 16: 2022 1132-1152
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
Nature 607: 2022 808-815
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL.
Blood Adv 7: 2023 6156-6162
TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.
Proc Natl Acad Sci U S A 121: 2024 e2320421121